Treatment with miR-223 agomirs in neutrophilic asthmatic mouse models attenuates airway inflammation, reduces NLRP3 levels, and decreases IL-1β release, suggesting miR-223 as a potential therapeutic candidate for severe non-T2 asthma (132). The gene discussed is NLRP3; the disease is asthma.